NCT01335191View on ClinicalTrials.gov

Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
HIV Infections
Interventions
BIOLOGICAL

TUTI-16 (1.0 mg)

Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.

OTHER

Placebo

Two subcutaneous injections of Placebo at Day 0 and Week 3.

Trial Locations (1)

10019

Clinilabs, New York

All Listed Sponsors
lead

Thymon, LLC

INDUSTRY

NCT01335191 - Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001) | Biotech Hunter | Biotech Hunter